| 1 | Title |
|----|--|
| 2 | Are there mortality improvements with newer interventions in adult cardiac surgery? Evidence |
| 3 | from 73 meta-analyses |
| 4 | |
| 5 | Short Title |
| 6 | Mortality improvements in adult cardiac surgery |
| 7 | |
| 8 | Austin Parish, MD, George Tolis, Jr., MD, John P.A. Ioannidis, MD, DSc |
| 9 | |
| 10 | Department of Emergency Medicine, Brookdale Hospital Medical Center, Brooklyn, New York, |
| 11 | 11212, USA (AP) |
| 12 | |
| 13 | Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA |
| 14 | 02115 (GT) |
| 15 | |
| 16 | Meta-Research Innovation Center at Stanford (METRICS), Stanford University, and Departments of |
| 17 | Medicine and of Epidemiology and Population Health, Stanford University School of Medicine, |
| 18 | Stanford, CA 94305, USA (JPAI) |
| 19 | |
| 20 | Address for Correspondence |
| 21 | George Tolis, Jr. MD, Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard |
| 22 | Medical School, 75 Francis Street, Boston MA 02115 Email : gtolis@bwh.harvard.edu |
| 23 | |
| 24 | Funding: none |

- 25 Disclosure statement: The authors have no conflicts of interest.
- 26 Data sharing statement: All data are available from the authors upon request.
- 27 Independent data access and analysis: The corresponding author as well as the remaining two authors
- had full access to all the data in the study. The corresponding author takes responsibility for its
- 29 integrity and the data analysis.

31 ABSTRACT

Background In the last two decades, many new interventions have been introduced with the ultimate goal of improving overall postoperative outcomes after cardiac operations in adults. We aimed to assess how often randomized controlled trials (RCTs) in adult cardiac surgery found significant mortality benefits for newer interventions versus older ones, whether observed treatment effect estimates changed over time and whether RCTs and non-randomized observational studies gave similar results.

Methods We searched journals likely to publish systematic reviews on adult cardiac surgery for
 meta-analyses of mortality outcomes and that included at least one RCT, with or without
 observational studies. Relative treatment effect sizes were evaluated overall, over time, and per study

41 design.

Results 73 meta-analysis comparisons (824 study outcomes on mortality, 519 from RCTs, 305 from 42 observational studies) were eligible. The median mortality effect size was 1.00, IQR 0.54-1.30 (1.00 43 among RCTs, 0.91 among observational studies, p=0.039). 4 RCTs and 6 observational studies 44 reached p<0.005 favoring newer interventions. 2/73 meta-analyses reached p<0.005 favoring the 45 newer interventions. Effect size for experimental interventions relative to controls did not change 46 47 over time overall (p=0.64) or for RCTs (p=0.30), and there was a trend for increase in observational studies (p=0.027). In 34 meta-analyses with both RCTs (n=95) and observational studies (n=305), the 48 median relative summary effect (summary effect in observational studies divided by summary effect 49 50 in RCTs) was 0.87 (IQR, 0.55-1.29); meta-analysis of the relative summary effects yielded a summary of 0.93 (95% CI, 0.74-1.18). 51

52 Conclusions The vast majority of newer interventions had no mortality differences over older ones 53 both overall and in RCTs in particular, while benefits for newer interventions were reported more 54 frequently in observational studies.

55 Keywords

56 cardiac surgery, mortality, death, meta-analysis, bias

57

58 Abbreviations

- 59 HR: hazard ratio
- 60 OR: odds ratio
- 61 RCT: randomized controlled trial
- 62 RR: risk ratio
- 63 SRMA: systematic review and meta-analysis
- 64

65 **INTRODUCTION**

Although adult cardiac surgery was officially introduced as a subspecialty of thoracic surgery 66 67 100 years ago with the first closed mitral commissurotomy (1), it did not become widely clinically applicable until more than three decades later, with the development of cardiopulmonary bypass (2). 68 The expanded treatment options afforded by cardiopulmonary bypass transformed the initial scattered 69 70 heroic interventions by a handful of surgeons into a surgical discipline with a strong clinical and 71 research record. Adult cardiac surgery has been shown to offer very effective interventions for 72 common conditions such as coronary artery disease, various valvulopathies and diseases of the great 73 vessels (3-6), and for some less common ones, e.g. intracardiac and thoracic tumors or abdominal 74 tumors with vascular extension into cardiac chambers (7,8). Many well-established effective 75 interventions are reproducible by a variety of academic and community-based surgeons. Nevertheless, there is also a large and rapidly growing literature in the field attempting to assess 76 77 newer interventions or modifications of established interventions. Benefits and advantages could come in different forms. A newer intervention may represent an invasive procedure treating a 78

79 previously medically observed, non-intervenable condition, or may involve a more

invasive/aggressive approach than the older procedure which has historically represented the gold
standard. Typically, the goal would be to show that the new intervention affords a mortality benefit in
order to justify it. Alternatively, a new intervention may not aim to improve mortality, but may be
considered to have less invasiveness (and hence perhaps fewer complications and/or lesser cost),
therefore rendering it preferable to the established standard-of-care if non-inferiority regarding
mortality could be demonstrated.

The gold standard for testing and evaluating treatment interventions is afforded by 86 87 randomized controlled trials (RCTs), especially when expected effects are likely to be modest and risk-benefit ratios need careful examination. Moreover, it is widely established that when many 88 RCTs exist, careful systematic review and meta-analysis may help examine the overall evidence to 89 hape guidance for eventual clinical decision-making. Many non-randomized studies are also 90 91 conducted and published. This is even more true for surgical specialties where RCTs may be difficult to conduct (9-11). These non-randomized (henceforth called observational) studies can also be 92 examined in meta-analyses and may also influence eventual guidance and decision-making. The 93 relative merits and comparative outcomes of observational versus randomized evidence has been 94 95 heavily contested and debated across diverse clinical areas across medicine. Some meta-research 96 evaluations have combined data from multiple meta-analyses where both RCTs and observational studies are available on the same topic (12-14). Some evaluations suggest that, on average, RCTs and 97 98 observational studies yield similar estimates of the treatment effect (12). Others have found that observational studies tend to have exaggerated estimates of benefit compared with RCTs (13,14). To 99 our knowledge, no such systematic evaluation has been performed including diverse topics in the 100 101 field of adult cardiac surgery, a field where many observational studies publish estimates of intervention effectiveness. 102

Here, we undertook a meta-research evaluation that systematically identified and analyzed meta-analyses of adult cardiac surgery interventions where the outcome was mortality and where at least one RCT was available. We aimed to assess how often RCTs in the field found significant benefits for newer interventions versus older ones or doing nothing; whether treatment effect estimates changed over time in the last several decades; and whether RCTs and observational studies on the same intervention comparison give similar results.

109 METHODS

110 Search strategy and eligibility criteria

This is a meta-research project (15) reported following the PRISMA 2020 checklist for 111 systematic reviews and meta-analyses (16), adapted to our specific meta-research design. 112 We considered as eligible all systematic reviews and meta-analyses (SRMAs) related to adult 113 cardiac surgery that contained randomized controlled trials (RCTs) (regardless of whether 114 observational non-randomized studies were also included or not) and summarized all-cause mortality 115 outcomes. We searched in publication venues likely to publish most of these adult cardiac surgery 116 SRMAs. Specifically, the search strategy captured for further screening all SRMAs published in the 117 Journal of Thoracic and Cardiovascular Surgery and Annals of Thoracic Surgery (the two primary 118 119 journals specializing in the field of interest) and all SRMAs that were likely to address cardiac 120 surgery in any of the 4 highest impact factor surgical journals, the 4 highest impact factor general medical journals, and the comprehensive Cochrane Database of Systematic Reviews. The complete 121 122 search string was ((Annals of Surgery [SO] OR Surgery [SO] OR JAMA Surgery [SO] OR British Journal of Surgery [SO] OR New England Journal of Medicine [SO] OR JAMA [SO] OR Lancet 123 [SO] OR BMJ [SO] OR Cochrane Database of Systematic Reviews [SO]) AND ('cardiac surgery' OR 124 125 'heart surgery' OR 'coronary bypass' OR CABG OR 'valve surgery')) OR (ann thorac surg[Journal]

126 OR j thorac cardiovasc surg[Journal]) AND (systematic[sb] OR meta-analysis[sb]). The search was

127 last updated on August 1^{st} , 2023.

128 Two authors (GT/AP) screened the abstracts of all retrieved items for eligibility. Items were 129 excluded if they were not SRMAs, not studying the effect of interventions on all-cause mortality, 130 contained no RCTs, or were studying topics unrelated to current adult cardiac surgery. When 131 SRMAs on the same comparison and outcomes (duplicates) were identified, the SRMA with most RCTs was included; with ties, we included the one that had more observational studies. 132 133 Data extraction from eligible meta-analyses 134 For all included eligible SRMAs, we extracted journal, year of publication, and data for allcause mortality outcomes, including the specific outcome, effect metric (odds ratio [OR], risk ratio 135 [RR], hazard ratio [HR], or incident rate ratio [IRR]), specific comparison (experimental and control 136 groups), the overall reported meta-analysis summary effect and effects from individual studies 137 (summarized in tables or forest plots). For each individual study, we extracted the effect size, 95% 138 confidence interval (CI), and the 2x2 table whenever available. When SRMAs presented all-cause 139 mortality outcomes for different timepoints, all timepoints were extracted. 140 The summary estimate presented by the authors in the SRMA was extracted. When both 141 142 adjusted and unadjusted study results were synthesized, we preferred the latter. For 22 SRMAs and a 143 total of 221 individual studies, a summary estimate was not available, but we could calculate OR from 2x2 tables of the individual studies and obtain the summary OR thereof. 144 145 For each comparison, we recorded whether the comparison was between an active experimental group and usual care, placebo (sham) or an active control group. We also assessed and 146 recorded the direction of each eligible comparison. Whenever an older intervention was the 147

experimental group and a newer intervention was the control group, we inverted the effect sizes (e.g.

149 3 became 1/3=0.33), so that eventually all comparisons in our analysis reflect the comparison of a

| 150 | newer intervention versus an older one (or nothing/placebo/sham). Accordingly, effect sizes (relative |
|-----|---|
| 151 | risks) <1.0 represent a reduction in mortality favoring the newer intervention. Whether such coining |
| 152 | (inversion) was needed was determined by consensus between all authors (AP/GT/JPAI) regarding |
| 153 | which intervention is newer. |
| 154 | Validation of data from primary studies |
| 155 | We randomly selected 30 individual studies from the 34 SRMAs that contained both RCTs |
| 156 | and observational studies (from a total of 400 individual studies, n=95 RCTs and n=305 |
| 157 | observational studies) and re-calculated the study effect to confirm the numerical effect reported by |
| 158 | the SRMA authors. |
| 159 | Statistical techniques |
| 160 | Random effects meta-analysis was carried out using the Sidik-Jonkman estimator (17). All |
| 161 | effects were log-transformed before meta-analysis. Heterogeneity was estimated with the Higgins and |
| 162 | Thompson's I ² statistic and Cochran's Q test (18,19). Meta-analysis calculations were performed |
| 163 | using the meta package in R (20). Continuous data was also summarized using medians and |
| 164 | interquartile ranges (IQR); the Spearman correlation coefficient was calculated between continuous |
| 165 | variables (21). |
| 166 | All comparisons of interventions were classified into two types, type A (comparing a newer |
| 167 | less invasive method versus an older more invasive method looking at non-inferiority) and type B |
| 168 | (comparing a newer more invasive method versus an older less invasive method looking at |
| 169 | superiority). Type B includes also all comparisons against doing nothing (or giving placebo/sham). |
| 170 | Sensitivity analyses were performed where the summary effect was inverted for all type A |
| 171 | comparisons. |
| | |

For those SRMAs that included also observational studies, we compared the results of RCTs
versus observational studies in each topic by obtaining the relative summary effect, i.e. the fixed

| 174 | effects summary effect across observational studies divided by fixed effects summary effect across |
|-----|---|
| 175 | RCTs) (22). We then synthesized the relative summary effects across all topics that included the |
| 176 | RCTs and observational studies. A relative summary effect <1.0 suggests that the observational |
| 177 | studies show better results for the newer intervention regarding mortality than RCTs. |
| 178 | Statistical significance was assessed at two levels, $\alpha = 0.05$ (suggestive significance) and $\alpha =$ |
| 179 | 0.005 (formal statistical significance), as proposed by Benjamin et al. (23). |
| 180 | R version 4.1.0 was used for all calculations (R Core Team 2021). |
| 181 | RESULTS |
| 182 | Eligible SRMAs and single studies |
| 183 | Our literature search identified 927 items. Of these, 531 (57%) were unrelated to cardiac |
| 184 | surgery, 170 (18%) included no RCTs (18%), 50 (5%) did not include mortality outcomes, 26 (3%) |
| 185 | were not SRMAs presenting extractable data, 23 (2%) were not studies of interventions, 31 (3.3%) |
| 186 | were repeat topics, and 1 was withdrawn. Of the 95 remaining publications of SRMAs, 61 (64%) |
| 187 | were found to have extractable data on mortality from forest plots and were included (Figure 1). For |
| 188 | the other 34 that had no clearly extractable data per study in forest plots, the corresponding authors |
| 189 | were contacted, but none offered usable data. Of the 61 publications, 25 (41%) were published in the |
| 190 | Journal of Thoracic and Cardiovascular Surgery, 22 (36%) in Annals of Thoracic Surgery, 12 (20%) |
| 191 | in the Cochrane Database of Systematic Reviews, and 2 (3%) in Annals of Surgery. |
| 192 | 10 of the 61 papers contained two or more different eligible comparisons (n=2 papers) or |
| 193 | timepoints for the comparison of the same intervention (n=8 papers). Overall, 73 different |
| 194 | comparisons were eligible for our analyses; of them, 6 (8%) were inverted to consistently have the |

newer (experimental) intervention compared against the older (control) intervention. The 73

196 comparisons are shown in **Supplementary Table 1.** They included a total of 824 mortality study

outcomes, 519 RCTs and 305 observational ones. Of the 824, 490 were presented as OR, 242 RR, 55

HR, and 37 IRR metrics. Across the 73 meta-analyses, each contained a median of 10 studies (IQR 6
to 17). Of the 73 meta-analyses, 29 (416 study outcomes) were type A comparisons and 44 (408

- study outcomes) were type B comparisons.
- 201 *Effect sizes and statistical significance in single studies*
- The median mortality effect size across 824 individual study outcomes was 1.00 (IQR, 0.54-

1.30), suggesting no difference in mortality, on average, between experimental and control

interventions. Across 519 RCTs, the median effect size was also 1.00 (IQR, 0.58-1.32), whereas

across 305 observational studies it was 0.91 (IQR, 0.50-1.26). The difference between RCTs and

206 observational studies suggested statistical significance (Wilcoxon rank sum p=0.039).

Across the 519 RCTs, 36 (6%) had suggestive significance (p<0.05), but only 11 (2%) were

formally statistically significant with p=0.005. Suggestive and formal significance was seen in 18

and 4 RCTs in favor of the newer (experimental) intervention and in 18 and 7 RCTs in favor of the

210 control intervention. When limited to the 277 RCTs of type B (presumably superiority) comparisons,

211 16 (6%) and 5 (2%) had suggestive and formal significance and almost always this favored the newer

212 intervention (**Table 1**).

Across the 305 observational studies, there were 38 (13%) and 10 (3%) with suggestive and formal statistical significance. Most of those favored the newer (experimental) intervention (27 and 6, respectively) and fewer favored the control intervention (11 and 4, respectively). When limited to 131 type B (presumably superiority) comparisons, 25 (19%) and 4 (3%) showed suggestive and formal

significance, almost always favoring the newer intervention (**Table 1**).

218 *Treatment effects over time*

A total of 122 RCTs and 125 observational studies had been published in the last decade

220 (2012 or later). The median effect size of these 247 studies was 1.00 (IQR, 0.50-1.26) overall (1.00,

IQR, 0.60-1.36 in RCTs and 0.86, IQR, 0.46-1.05 in observational studies). The majority of

statistically significant RCTs with p<0.005 (8/11, 73%) were published in the last decade and of
these, 6/8 (75%) were in favor of the control intervention. Conversely, among observational studies
with p<0.005, 6/10 (60%) had been published in the last decade and 5/6 (83%) were in favor of the
newer (experimental) intervention (**Table 1**).
There was no significant change in the effect size for newer versus control interventions over
time (p=0.56, p=0.55 after controlling for specific comparisons). For RCTs, there was no significant

time effect (p=0.42; after adjusting for specific comparisons, p=0.40). For observational studies, there

229 was a suggestion of a time association with a trend for increasing effects over time (p=0.049; after

adjusting for specific comparisons, p=0.065) (**Figure 2**).

231 Treatment effects in meta-analyses

As reported by the authors, the median meta-analysis summary effect across 73 comparisons was 0.90 (IQR, 0.69-1.12). Of the 73 meta-analyses, as reported by the authors, 15 (21%) had summary effects with suggestive significance with p<0.05 and 4 (5%) had summary effects that were statistically significant with p<0.005 level in favor of the experimental arm, while 6 (8%) and 3 (4%) meta-analyses had effects at these significance levels favoring the control arm. When we re-analyzed the data with random effects and the SJ method, the respective numbers were 5, 2, 3 and 1.

When limited to data from the 519 RCTs outcomes, the median meta-analysis summary effect was 0.94 (IQR, 0.74 to 1.19); of the 73 meta-analyses based on RCT data, only 2 were statistically significant (p<0.005) in favor of the experimental arm and 2 in favor of the control arm.

When limited to type B (presumably superiority) comparisons (44 meta-analyses total), 14 meta-analyses had summary effects with suggestive significance with p<0.05 and 4 had summary effects that were statistically significant with p<0.005 in favor of the experimental arm; conversely, only 1 and 0 meta-analyses had effects at these significance levels favoring the control arm. When limited to data from the RCTs, the respective numbers were 7, 2, 0, and 0.

246 Clinical topics with statistically significant differences

| 247 | Table 2 shows the 7 clinical topics where there were statistically significant differences in |
|-----|---|
| 248 | mortality at the p<0.005 level in the meta-analyses, as originally reported by the systematic review |
| 249 | authors, 3 of which retained p<0.005 in our re-calculated SJ random effects estimates. |
| 250 | Relative effects in RCTs and observational studies |
| 251 | Of 73 meta-analyses, 34 (47%) contained at least one RCT and at least one observational |
| 252 | study; across these 34 meta-analyses there were 400 individual studies (95 were RCTs (24%) and 305 |
| 253 | observational studies). The median observational summary effect was 0.81 (IQR, 0.68-1.05) vs 0.93 |
| 254 | (IQR, 0.77-1.22) in the respective RCTs (paired Wilcoxon p=0.17). The Spearman correlation |
| 255 | between RCT and observational summary effect sizes was -0.023 (p=0.90). |
| 256 | The relative summary effect (summary effect in observational studies divided by summary |
| 257 | effect in RCTs) had a median of 0.87 (IQR, 0.55-1.29); meta-analysis of the relative summary effects |
| 258 | yielded a summary of 0.93 (95% CI 0.74-1.18, p=0.57, I ² =0%, 0-39%) (Figure 3). Respective results |
| 259 | were 0.86 (IQR, 0.41-1.04) and 0.85 (95% CI, 0.55-1.34, p=0.85, $I^2 = 0\%$, 0%-57%) for type A |
| 260 | comparisons and 1.08 (IQR, 0.78-1.44) and 0.98 (95% CI, 0.75-1.27, p=0.85, I ² =0%, 0%-47%) for |
| 261 | type B comparisons. |
| 262 | Sensitivity analyses yielded similar results (see Supplementary Results). |
| 263 | Validation of primary data |
| 264 | In the 30 randomly selected studies (from 22 SRMAs), our re-calculated study effect was |
| 265 | always the same or very similar (maximum deviation 0.04 in relative risk scale) to the effect reported |
| 266 | by the SRMA authors. |
| | |

267 **DISCUSSION**

268 Our analysis of 73 comparisons of newer interventions versus control management in adult 269 cardiac surgery shows that mortality benefits of new interventions versus older approaches were

uncommon. The median effect size of 1.00 suggests no difference in mortality between the compared 270 271 groups. The same picture was seen when examining strictly the data from RCTs. Conversely, on 272 average, observational data suggested some benefit for the experimental intervention groups. 273 Evidence from RCTs rarely suggested statistically significant benefits of the experimental 274 intervention at the level of single studies or meta-analyses thereof. Conversely, a modest fraction of 275 non-randomized observational data suggested significant benefits for the experimental arm. Effect 276 sizes in RCTs have been steady over time, while effect sizes for non-randomized observational data 277 may tend to become larger in more recent years. 278 Only about half of the 73 topics that we examined included both RCTs and observational data 279 in their meta-analyses. Moreover, very few RCTs were included in these topics where a direct comparison of effect sizes RCTs versus observational studies would be feasible within the same 280

topic. Therefore, the results from these direct comparisons have large CIs and are underpowered to

detect clear differences between the two designs. Nevertheless, the picture in this subset is

compatible with the overall picture across all 73 comparisons.

There is debate about the merits and uses of non-randomized observational studies to evaluate comparative effectiveness (24,25). Our findings suggest caution in making definitive inferences and formulating guidelines about comparative effectiveness based on observational data in adult cardiac surgery. Observational data have more degrees of freedom and this may result in higher chances of selective reporting that fits some expected narrative. RCTs certainly have their own biases and they are not infallible gold standards. Nevertheless, the effort to promote the use of RCTs in surgery is welcome (26).

The dearth of well-documented benefits in mortality with newer, experimental interventions in adult cardiac surgery does not mean that the field does not make progress. Half of the data that we analyzed pertained to type A comparisons, where the newer intervention was a less invasive one and

294 thus the goal would probably not be to show necessarily better survival, but other comparative 295 benefits, e.g. fewer complications, better convenience or lesser cost. Moreover, among the 296 comparisons that had a superiority outlook with the newer intervention being more aggressive than 297 the control, we could identify two where the newer intervention did significantly better in mortality 298 outcomes than the control at p<0.005. Both of them reflected classic, widely-used interventions 299 where the magnitude of the survival benefit was very large, i.e. use of intra-aortic balloon pump and 300 surgery for asymptomatic severe aortic stenosis. For new and future interventions, one may need to 301 be prepared to detect much smaller but still clinically meaningful survival benefits. This would

require larger studies to have sufficient power to detect such benefits with certitude.

We evaluated results both at the level of effect sizes and at the level of statistical significance. 303 Effect sizes are preferable to convey the magnitude of the potential benefit (27). Nevertheless, we 304 305 should caution that the data are typically presented in relative effect metrics. Clinical decisionmaking should also examine carefully the absolute magnitude of benefits. Also for statistical 306 significance, some authors argue that dichotomizing p-values may be spurious and misleading and 307 308 have even urged to abandon the notion of statistical significance (28). Nevertheless, for clinical trials and their SRMAs (as analyzed here), the notion of statistical significance still has relevance: its 309 310 abandonment may open the door to even more spurious practices, where investigators may move the 311 goalposts without any statistical rules (29). The use of p<0.005 instead of p<0.05 is recommended to avoid false-positive results (23). This suggestion has also empirical grounding in RCTs and meta-312 313 analyses thereof (30).

Our study has some limitations. First, we only focused on SRMAs published in the key journals that are likely to publish SRMAs in this specialty, as it would have been inconvenient and low-yield to screen hundreds of thousands of SRMAs published across the entire medical literature. Second, SRMAs may not have been performed yet on some interesting topics and this may affect

more prominently recent developments in the field with very recent data. Third, while most of the 318 319 included data used OR metrics, some used other relative effect metrics and these are not identical. 320 Nevertheless, for the mostly small effects analyzed here, differences between OR and HR, RR, or 321 IRR are probably small. Fourth, while we took meticulous care with data, we depended in existing 322 published SRMAs and these evidence syntheses may include their own biases and errors. There are 323 many efforts to improve the methodological rigor of conduct and the quality of reporting of both 324 primary studies and of SRMAs (31). The importance of enhanced attention to these matters cannot be 325 overstated. Fifth, we could not evaluate whether improved outcomes with new interventions may 326 exist specifically for subgroups of patients, e.g. in recent years there has been an expansion of the pool of surgical candidates. Patients who were considered inoperable in the past due to advanced age 327 or underlying conditions are routinely offered surgery in the current era. Finally, no single study and 328 329 no single SRMA can be taken as perfect evidence, no matter how well it is done. Therefore, 330 uncertainty about the comparative effects of different interventions may be larger than actually observed. 331

Allowing for these caveats, our meta-research analysis offers a bird's eye view of over 800 study effect size estimates from comparisons involving adult cardiac surgery These data can be used as a benchmark for what might be reasonable expectations for future RCT and comparative effectiveness research and SRMAs in the field.

336

337 **References**

- (1) Cutler EC, Levine SA. Cardiotomy and valvulotomy for mitral stenosis. Boston Med Surg J
 1923;188:1023-7.
- 340 (2) Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn
 341 Med 1954;37(3):171-185.
- 342 (3) Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery bypass
 343 surgery. Survival data. Circulation 1983;68(5):939-950.
- (4) Carabello BA. Clinical practice. Aortic stenosis. N Engl J Med 2002:346-677.
- 345 (5) David TE. Aortic valve repair and aortic valve-sparing operations J Thorac Cardiovasc Surg
 346 2015;149:9.
- 347 (6) Carpentier A. Cardiac valve surgery: the "grench correction." J Thorac Cardiovasc Surg
 348 1983;86:323.
- 349 (7) Dein JR, Frist WH, Stinson EF, et al: Primary cardiac neoplastms: early and late results of
 350 surgical treatment in 42 patients. J Thorac Cardiovasc Surg 1987;93:502.
- (8) Bossert Torsten B, Gummert JF, Battellini, et al. Surgical experience with 77 primary cardiac
 tumors. Interact Cardiovasc Thorac Surg 2005;4:311-315.
- (9) Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM, Balliol Collaboration, et al.
 Evaluation and stages of surgical innovations. Lancet. 2009;374:1089–96.
- 355 (10) Gelijns AC, Ascheim DD, Parides MK, Kent KC, Moskowitz AJ. Randomized trials
 356 in surgery. 2009;145:581–7.
- 357 (11) Ergina PL, Cook JA, Blazeby JM, Boutron I, Clavien P-A, Reeves BC, et al.
- 358 Challenges in evaluating surgical innovation. Lancet. 2009;374:1097–104.

| 359 | (12) | Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational |
|-----|-------|---|
| 360 | study | designs compared with those assessed in randomized trials. Cochrane Database Syst |
| 361 | Rev. | 2014 Apr 29:2014(4):MR000034. |

- 362 (13) Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment
 363 effects for mortality from routinely collected data and subsequent randomized trials: meta 364 epidemiological survey. BMJ. 2016 Feb 8;352:i493.
- 365 (14) Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG,

366 Contopoulos-Ioannidis DG, Lau J. Comparison of evidence of treatment effects in

randomized and nonrandomized studies. JAMA. 2001 Aug 15;286(7):821-30.

368 (15) Lozada-Martinez ID, Ealo-Cardona CI, Marrugo-Ortiz AC, Picón-Jaimes YA,

369 Cabrera-Vargas LF, Narvaez-Rojas AR. Meta-research studies in surgery: a field that should

be encouraged to assess and improve the quality of surgical evidence. Int J Surg. 2023 Jun
1;109(6):1823-1824.

IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014 Feb 18;14:25.

375 (17) Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,

376 Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM,

- 377 Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA,
- 378 Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020
- 379statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021
- 380 Apr;88:105906.
- 381 (18) Sedgwick P. Meta-analyses: what is heterogeneity? BMJ. 2015 Mar 16;350:h1435.

382 (19) von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses.

383 BMC Med Res Methodol. 2015 Apr 14;15:35.

- 384 (20) Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a
- practical tutorial. Evid Based Ment Health. 2019 Nov;22(4):153-160.
- 386 (21) de Winter JCF, Gosling SD, Potter J. Comparing the Pearson and Spearman
- 387 correlation coefficients across distributions and sample sizes: A tutorial using simulations and
- empirical data. Psychological Methods 2016;21(3):273–290.
- 389 (22) Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and
- discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med.
- 391 2001 Dec 4;135(11):982-9.
- 392 (23) Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers EJ, Berk R, et al.
 393 Redefine statistical significance. Nat Hum Behav. 2018 Jan;2(1):6-10.
- 394 (24) Gerstein HC, McMurray J, Holman RR. Real-world studies no substitute for RCTs in
 395 establishing efficacy. Lancet. 2019 Jan 19;393(10168):210-211.
- 396 (25) Djulbegovic B, Glasziou P, Chalmers I. The importance of randomised vs non
 397 randomised trials. Lancet. 2019 Aug 24;394(10199):634-635.
- 398(26)McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al.

No surgical innovation without evaluation: the IDEAL recommendations. Lancet.

400 2009;374:1105–12.

401 (27)

- 402 Ioannidis JPA. Options for publishing research without any P-values. Eur Heart J. 2019 Aug
 403 14;40(31):2555-2556.
- 404 (28) Amrhein V, Greenland S, McShane B. Scientists rise up against statistical
 405 significance. Nature. 2019 Mar;567(7748):305-307.

| 406 | (29) | Ioannidis JPA. Retiring statistical significance would give bias a free pass. Nature. |
|-----|-------|---|
| 407 | 2019 | Mar;567(7749):461. |
| 408 | (30) | Koletsi D, Solmi M, Pandis N, Fleming PS, Correll CU, Ioannidis JPA. Most |
| 409 | reco | mmended medical interventions reach $P < 0.005$ for their primary outcomes in meta- |
| 410 | analy | yses. Int J Epidemiol. 2020 Jun 1;49(3):885-893. |
| 411 | (31) | Kolaski K, Logan LR, Ioannidis JPA. Guidance to best tools and practices for |
| 412 | syste | ematic reviews. JBI Evid Synth. 2023;21(9):1699-1731. |
| 413 | | |

- **Table 1.** RCTs and non-randomized observational studies with suggestive (p<0.05) and formally
- statistically significant (p<0.005) results according to type of comparison and year of publication.

| | p < 0.05, | p < 0.005, | p < 0.05, | p < 0.005, |
|---------------------|--------------|--------------|--------------|--------------|
| | favoring | favoring | favoring | favoring |
| | experimental | experimental | control | control |
| | intervention | intervention | intervention | intervention |
| PER TYPE OF | | | | |
| COMPARISON | | | | |
| RCT, type A | 3 (1%) | 0 (0%) | 17 (7%) | 6 (2%) |
| (n=242) | | | | |
| RCT, type B | 15 (5%) | 4 (1%) | 1 (0.4%) | 1 (0.4%) |
| (n=277) | | | | |
| Observational, type | 7 (4%) | 3 (2%) | 6 (3%) | 3 (2%) |
| A (n=174) | | | | |
| Observational, type | 20 (15%) | 3 (2%) | 5 (4%) | 1 (1%) |
| B (n=131) | | | | |
| PER YEAR OF | | | | |
| PUBLICATION | | | | |
| RCT | 7 (5.7%) | 2 (1.6%) | 14 (11.5%) | 6 (4.9%) |
| 2012-21 (n = 122) | | | | |
| RCT | 11 (2.8%) | 2 (0.5%) | 4 (1.0%) | 1 (0.3%) |
| pre-2012 (n = 397) | | | | |
| Observational | 14 (11.2%) | 5 (4.0%) | 2 (1.6%) | 1 (0.8%) |
| 2012-21 (n = 125) | | | | |

| Observational | 13 (7.2%) | 1 (0.6%) | 9 (5.0%) | 3 (1.7%) |
|--------------------|-----------|----------|----------|----------|
| pre-2012 (n = 180) | | | | |

416

| 417 | Type A comparisons involve comparing a newer less invasive method versus an older more invasive |
|-----|--|
| 418 | method, thus presumably demonstration of non-inferiority might be sufficient to make the newer |
| 419 | approach attractive. Type B comparisons involve comparing a newer more invasive method versus |
| 420 | an older less invasive method, thus presumably demonstration of superiority would be needed to |
| 421 | show that the added invasiveness is worthwhile. Type B includes also all comparisons against doing |
| 422 | nothing (or giving placebo/sham). |
| 423 | |

Table 2. Clinical topics with statistically significant survival differences at p<0.005 in meta-analyses

426

| Intervention (type A or B) | Condition/ Setting | Metric | Author reported meta- analysis effect | SJ random effects meta-analysis effect | RCTs only random effects meta-analysis effect | Mortality follow-up |
|---|---------------------------------------|--------|---|--|--|--------------------------|
| Loading dose vs regular dose of statins (B) | Prophylactic after CABG | OR | 0.74 (0.60-0.91) | 0.78 (0.57-1.06) | 0.78 (0.57-1.06) | 1 to 10 years |
| Off-pump vs on-pump (A) | CABG | HR | 1.07 (1.03-1.11) | 1.04 (0.95-1.14) | 1.20 (0.81-1.76) | 5 year |
| IABP vs No IABP (B) | Pre-op prophylactic before CABG | OR | 0.35 (0.23-0.53) | 0.36 (0.20-0.65) | 0.25 (0.11-0.56) | In-hospital or 30-day |
| Radial artery versus saphenous vein as the second conduit (B) | CABG | IRR | 0.74 (0.63-0.87) | 0.72 (0.54-0.95) | 0.94 (0.61-1.44) | 0.7 to 11.9 years |
| Early surgery vs conservative management (B) | Asymptomatic severe AS | HR | 0.49 (0.36-0.68) | 0.48 (0.32-0.72) | 0.33 (0.12-0.91) | 1.8 to 6.2 years |
| TAVR PCI vs SAVR CABG (A) | CABG | HR | 1.35 (1.11-1.65) | 1.34 (1.05-1.71) | 1.34 (1.05-1.71) | 1 to 3 years |
| PCI vs CABG (A) | Diabetic patients | OR | 1.64 (1.30-2.08) | 1.63 (1.23-2.17) | 1.63 (1.23-2.17) | 5 year |

427

- 428 AS: aortic stenosis, CABG: Coronary artery bypass graft, CI: confidence interval, IABP: Intra-aortic
- 429 balloon pump, PCI: percutaneous coronary intervention
- 430 Follow-up shows the time of mortality assessment.

- 432
- 433
- 434
- 435
- 436

437 Figure legends

- 438 **Figure 1.** Flow chart for eligible meta-analyses
- 439 Figure 2. Study effect size vs year of publication, with associated line of best fit, for observational
- 440 studies (n = 305) and RCTs (n = 519)
- 441 Figure 3. Forest plot of relative summary effect (summary effect in observational studies divided by
- summary effect in RCTs).
- 443
- 444
- 445
- 446
- 447
- 448
- 449
- 450





FIGURE 2



491 FIGURE 3

| Comparison | Risk Ratio | RR | 95%-CI |
|----------------------|------------------|--------|--------------|
| 1 | | 0.45 | [0.21; 0.92] |
| 2 | | 0.46 | [0.15; 1.37] |
| 3 | - 1 | 1.31 | [0.73; 2.32] |
| 4 | | 0.82 | [0.38; 1.74] |
| 5 | | 2.74 [| 0.22; 34.74] |
| 6 | ÷. | 0.93 | [0.68; 1.27] |
| 7 — | | 0.24 | [0.01; 6.22] |
| 8 | | 0.54 | [0.09; 3.32] |
| 9 | | 1.16 | [0.36; 3.75] |
| 10 | <u>+</u> * | 1.63 | [0.66; 4.01] |
| 11 | | 0.79 | [0.52; 1.21] |
| 12 | | 1.44 | [0.36; 5.76] |
| 13 | | 1.08 | [0.21; 5.50] |
| 14 | | 1.18 | [0.48; 2.93] |
| 15 | | 1.25 | [0.17; 9.16] |
| 10 | | 0.02 | [0.20, 0.30] |
| 17 | | 0.41 | [0.37, 2.95] |
| 10 | 1 | 1.04 | [0.02, 9.24] |
| 20 | . | 0.78 | [0.11: 5.41] |
| 20 | L | 1.69 | [0.97 2.96] |
| 21 | | 0.41 | [0.04, 4.53] |
| 23 | | 1.62 | [0.58 4.59] |
| 24 | | 0.48 | [0.06: 3.72] |
| 25 | | 0.86 | [0.26; 2.87] |
| 26 | — <u> </u> + — — | 2.87 | 0.34; 23.95] |
| 27 | | 0.61 | [0.32; 1.19] |
| 28 | | 0.86 | [0.30; 2.50] |
| 29 | | 0.87 | [0.46; 1.65] |
| 30 | | 0.17 | [0.01; 3.93] |
| 31 | - <u>+</u> + | 1.65 | [0.46; 5.97] |
| 32 | | 0.31 | [0.07; 1.45] |
| 33 | | 0.60 | [0.17; 2.15] |
| 34 | | 4.20 | 0.48; 36.86] |
| Common effect model | ļ | 0.04 | 0 04. 4 001 |
| Random effects model | l | 0.94 | [0.61, 1.09] |
| Γ | | 0.93 | [0.74; 1.18] |
| 0.01 | 0.1 1 10 | 100 | |
| | | | |

Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0.1574$, p = 0.75

492

493

- 495 **Supplementary Table 1**. 73 comparisons (comparison-outcome pairs) across 61 SRMAs.
- 496 *Abbreviations*: ECMO: Extra Corporeal Membrane Oxygenation. PCI: Percutaneous Coronary
- 497 Intervention. CABG: Coronary Artery Bypass Grafting. ARDS: Acute Respiratory Distress
- 498 Syndrome. DAPT: Dual Anti-Platelet Therapy. SAPT: Single Anti-Platelet Therapy. TAVR:
- 499 Transcatheter Aortic Valve Replacement. AVR: Aortic Valve Replacement. IABP: Intra-Aortic
- 500 Balloon Pump. TVA: Tricuspid Valve Annuloplasty. OPCAB: Off Pump Coronary Artery Bypass.
- 501 SAVR: Surgical Aortic Valve Replacement (same as AVR). MIDCAB: Minimally Invasive Direct
- 502 Coronary Artery Bypass.
- 503

| Comparison | | | |
|------------|---|-------------------|-----------------|
| Number | | | Outcome |
| From Fig 3 | Title of SRMA | Comparison | Name |
| | | Surgical ablation | |
| | | vs No ablation, | |
| | Expert consensus guidelines: Examining | just index | 30 day |
| 1 | surgical ablation for atrial fibrillation | operation | mortality |
| | | | Death at latest |
| | Percutaneous coronary invervention versus | | available |
| | coronary artery bypass grafting: a meta- | | follow-up time |
| | analysis | PCI vs CABG | point |
| | Contemporary extracorporeal membrane | ECMO vs | |
| | oxygenation therapy in adults: | "Endotracheal | Death at |
| | Fundamental principles and systematic | ventilation +/- | primary |
| | review of the evidence | mechanical assist | endpoint |

| | | devices" for | |
|---|--|-----------------|-----------------|
| | | ARDS patients | |
| | N-acetylcysteine in cardiovascular- | NAC vs no | |
| | surgery-associated renal failure: a meta- | adjunct | |
| | analysis | medication | Mortality |
| | | Chlorhexidine | |
| | | mouthwash vs No | |
| | Preoperative chlorhexidine mouthwash to | preop skin prep | |
| | reduce pneumonia after cardiac surgery: A | (outside of | In-hospital |
| | systematic review and meta-analysis | operating room) | mortality |
| | Comparing Single- and Dual-Antiplatelet | | Short-term all- |
| | Therapies After Transcatheter Aortic Valve | DAPT vs SAPT | cause |
| 2 | Implantation | after TAVR | mortality |
| | Comparing Single- and Dual-Antiplatelet | | Long-term all- |
| | Therapies After Transcatheter Aortic Valve | DAPT vs SAPT | cause |
| 3 | Implantation | after TAVR | mortality |
| | Ring or suture annuloplasty for tricuspid | RING vs NO | Early mortality |
| 4 | regurgitation? A meta-analysis review | RING | after surgery |
| | A Meta-Analysis of Miniaturized Versus | | |
| | Conventional Extracorporeal Circulation in | | |
| 5 | Valve Surgery | MECC vs CECC | Mortality |
| | Closure of the sternum with anchoring of | | |
| | the steel wires: Systematic review and | Anchoring vs no | |
| | meta-analysis | anchoring | Death |

| | Meta-Analysis of Medium and Long-Term | Loading dose of | |
|---|--|--------------------|-----------------|
| | Meta-Analysis of Metalum and Long-Term | Loading dose of | |
| | Efficacy of Loading Statins After Coronary | statins vs regular | |
| | Artery Bypass Grafting | dose of statins | Mortality |
| | Worse long-term survival after off-pump | | 5 year all- |
| | than on-pump coronary artery bypass | Off-pump vs on- | cause |
| 6 | grafting | pump CABG | mortality |
| | Beating-Heart Versus Conventional On- | | |
| | Pump Coronary Artery Bypass Grafting: A | BH-ONCAB vs | |
| 7 | Meta-Analysis of Clinical Outcomes | C-ONCAB | Early mortality |
| | Mitral valve surgery: right lateral | | All-cause |
| | minithoracotomy or sternotomy? A | | mortality up to |
| 8 | systematic review and meta-analysis | MIV vs Conv | 30 days |
| | Outcomes of Coronary Artery Bypass and | | |
| | Stents for Unprotected Left Main Coronary | Stenting vs | Medium-term |
| | Stenosis | CABG | death |
| | | Coated vs | |
| | A systematic review of biocompatible | Standard | |
| | cardiopulmonary bypass circuits and | cardiopulmonary | |
| | clinical outcome | bypass tubing | Death |
| | Gentamicin-collagen sponge reduces the | Gentamycin | |
| | risk of sternal wound infections after heart | sponge vs No | |
| 9 | surgery: Meta-analysis | prophylaxis | Mortality |
| | Volatile anesthetics in preventing acute | | All-cause |
| | kidney injury after cardiac surgery: a | Volatile vs TIVA | mortality |

| | systematic review and meta-analysis | | |
|----|--|--------------------|----------------|
| | Preoperative Prophylactic Intraaortic | | |
| | Balloon Pump Reduces the Incidence of | | Short-term |
| | Postoperative Acute Kidney Injury and | | death in high- |
| | Short-Term Death of High-Risk Patients | | risk patients |
| | Undergoing Coronary Artery Bypass | | undergoing |
| | Grafting: A Meta-Analysis of 17 Studies | IABP vs No IABP | CABG |
| | | Radial artery | |
| | | versus saphenous | |
| | | vein as the second | |
| | Radial artery versus saphenous vein as the | conduit for | |
| | second conduit for coronary artery bypass | coronary artery | Long-term |
| 11 | surgery: A meta-analysis | bypass surgery | mortality |
| | Treatment options for ischemic mitral | MitraCLIP + | |
| 12 | regurgitation: A meta-analysis | OMT vs OMT | Mortality |
| | Treatment options for ischemic mitral | CABG + RMA vs | |
| | regurgitation: A meta-analysis | CABG | Mortality |
| | | RMA + | |
| | Treatment options for ischemic mitral | subvalvular vs | |
| 13 | regurgitation: A meta-analysis | subvalvular | Mortality |
| | Antithrombotic Strategies After | Dual antiplatelet | |
| | Bioprosthetic Aortic Valve Replacement: | therapy vs AVA | 30-day |
| | A Systematic Review | after TAVR | mortality |
| | Antithrombotic Strategies After | Warfarin vs ASA | 90-day |

| | Bioprosthetic Aortic Valve Replacement: | after surgical | mortality |
|----|---|---------------------|-----------------|
| | | | |
| | A Systematic Review | bioprosthetic | |
| | | AVR | |
| | Biatrial Versus Bicaval Orthotopic Heart | | |
| | Transplantation: A Systematic Review and | | |
| 14 | Meta-Analysis | Bicaval vs biatrial | Early mortality |
| | Supplemental Cardioplegia During Donor | Supplemental | |
| | Heart Implantation: A Systematic Review | cardioplegia vs | Perioperative |
| 15 | and Meta-Analysis | not | mortality |
| | Skeletonized internal thoracic artery | | |
| | harvest improves prognosis in high-risk | Skeletonized vs | |
| | population after coronary artery bypass | pedicled | |
| 16 | surgery for good quality grafts | harvesting | Mortality |
| | Single- versus multidose cardioplegia in | | |
| | adult cardiac surgery patients: A meta- | Single vs multi- | Operative |
| 17 | analysis | dose cardioplegia | mortality |
| | Automated Fastener vs Hand-tied Knots in | | |
| | Heart Valve Surgery: A Systematic | COR-KNOT vs | |
| 18 | Review and Meta-analysis | Hand-tie | Mortality rates |
| | Drug-eluting stents versus coronary artery | | |
| | bypass grafting for the treatment of | | All-cause |
| | coronary artery disease: a meta-analysis of | Drug eluting | mortality at 12 |
| 19 | randomized and nonrandomized studies | strent vs CABG | months |
| | A meta-analysis of transcatheter aortic | TAVI vs surgical | Early all-cause |

| | · · · · · · · · · | | . 1. |
|----|---|--------------------|-----------------|
| | valve implantation versus surgical aortic | AVR for aortic | mortality |
| | valve replacement | stenosis | |
| | | Concomitant | |
| | | tricuspid valve | |
| | | repair vs non- | |
| | | repair during left | |
| | | sided valve | |
| | | surgery for mild | |
| | Repair of Less Than Severe Tricuspid | or moderate | |
| | Regurgitation During Left-Sided Valve | tricuspid valve | |
| 20 | Surgery: A Meta-Analysis | regurgitation | Early mortality |
| | | Concomitant | |
| | | tricuspid valve | |
| | | repair vs non- | |
| | | repair during left | |
| | | sided valve | |
| | | surgery for mild | |
| | Repair of Less Than Severe Tricuspid | or moderate | |
| | Regurgitation During Left-Sided Valve | tricuspid valve | Late, all-cause |
| 21 | Surgery: A Meta-Analysis | regurgitation | mortality |
| | Difference in spontaneous myocardial | | |
| | infarction and mortality in percutaneous | | |
| | versus surgical revascularization trials: A | | All-cause |
| | systematic review and meta-analysis | PCI vs CABG | mortality |

| | | | Early death |
|----|---|------------------|------------------|
| | | | (this study also |
| | | | reports HR of |
| | | | all-cause |
| | Rapid deployment or sutureless versus | | mortality |
| | conventional bioprosthetic aortic valve | RDAVR vs | during follow- |
| 22 | replacement: A meta-analysis | CAVR | up period) |
| | | Early surgery vs | |
| | | conservative | |
| | | management for | |
| | Early surgery versus conservative | asymptomatic, | |
| | management of asymptomatic severe aortic | severe aortic | All-cause |
| 23 | stenosis: A meta-analysis | stenosis | mortality |
| | | Rigid plate | |
| | | fixation vs wire | |
| | Rigid Plate Fixation Versus Wire Cerclage | cerclage in | |
| | for Sternotomy After Cardiac Surgery: A | cardiac surgery | 30-day |
| 24 | Meta-Analysis | pts | mortality |
| | | | Perioperative |
| | | | mortality in |
| | | | patients |
| | A meta-analysis of minimally invasive | | undergoing |
| | versus conventional sternotomy for aortic | MIAVR vs | minimally |
| 25 | valve replacement | CAVR | invasive aortic |

| | | | valve |
|----|---|-------------------|-----------------|
| | | | varve |
| | | | replacement |
| | | Levosimendan vs | |
| | Meta-Analysis of Trials on Prophylactic | No additional | |
| | Use of Levosimendan in Patients | medication | Mortality at 30 |
| | Undergoing Cardiac Surgery | administration | days |
| | Adjunct retrograde cerebral perfusion | Aortic arch | |
| | provides superior outcomes compared with | surgery with HCA | 30 day or in- |
| | hypothermic circulatory arrest alone: A | alone versus HCA | hospital |
| 26 | meta-analysis | with RCP | mortality |
| | Off-pump versus on-pump coronary | Off-pump versus | Long-term |
| | revascularization: meta-analysis of mid- | on-pump coronary | mortality (N=3 |
| 27 | and long-term outcomes | revascularization | RCTs) |
| | Complete transcatheter versus surgical | | |
| | approach to aortic stenosis with coronary | | |
| | artery disease: A systematic review and | TAVR PCI vs | 30-day |
| 28 | meta-analysis | SAVR CABG | mortality |
| | Complete transcatheter versus surgical | | |
| | approach to aortic stenosis with coronary | | All-cause |
| | artery disease: A systematic review and | TAVR PCI vs | mortality |
| | meta-analysis | SAVR CABG | follow-up |
| | A systematic review and meta-analysis of | | |
| | in situ versus composite bilateral internal | In situ vs | All-cause |
| 29 | thoracic artery grafting | composite BITA | mortality |

| | Systematic review and meta-analysis of | Chordal | |
|----|--|-------------------|-----------------|
| | chordal replacement versus leaflet | replacement vs | |
| | resection for posterior mitral leaflet | leaflet resection | Perioperative |
| 30 | prolapse | techniques | mortality |
| | Mitral valve surgery and coronary artery | | |
| | bypass grafting for moderate-to-severe | | |
| | ischemic mitral regurgitation: Meta- | CABG + mital | |
| | analysis of clinical and echocardiographic | valve surgery vs | Perioperative |
| 31 | outcomes | CABG alone | mortality |
| | | Intervention vs | |
| | Systematic review and meta-analysis of | No additional | |
| | randomized controlled trials assessing | posterior | |
| | safety and efficacy of posterior pericardial | pericardial | |
| | drainage in patients undergoing heart | drainage tube | Death after |
| | surgery | placement | heart surgery |
| | Meta-analysis of valve hemodynamics and | Stentless vs | |
| | left ventricular mass regression for | stented aortic | Mortality at 1 |
| | stentless versus stented aortic valves | valves | year followup |
| | Effects of dipyridamole in combination | | |
| | with anticoagulant therapy on survival and | | |
| | thromboembolic events in patients with | Warfarin + | |
| | prosthetic heart valves. A meta-analysis of | dipyrimadole vs | |
| | the randomized trials | warfarin alone | Total mortality |
| | Minimally invasive direct coronary artery | MIDCAB vs PCI | Early mortality |

| | bypass graft surgery or percutaneous | for proximal left | |
|----|--|--------------------|-----------------|
| | coronary intervention for proximal left | anterior | |
| | anterior descending artery stenosis: a meta- | descending artery | |
| | analysis | stenosis | |
| | Minimally invasive direct coronary artery | MIDCAB vs PCI | |
| | bypass graft surgery or percutaneous | for proximal left | |
| | coronary intervention for proximal left | anterior | |
| | anterior descending artery stenosis: a meta- | descending artery | |
| | analysis | stenosis | Late mortality |
| | Stenting versus coronary artery bypass | PCI-S vs CABG | |
| | grafting for unprotected left main coronary | for unprotected | |
| | artery disease: a meta-analysis of | left main coronary | |
| 34 | comparative studies | artery disease | Death |
| | Pexelizumab in ischemic heart disease: a | Pexelizumab vs | |
| | systematic review and meta-analysis on | Placebo for | |
| | 15,196 patients | CABG | Death |
| | | Preoperative | |
| | | physical therapy | |
| | | versus no | Post-operative |
| | Preoperative physical therapy for elective | preoperative | death all |
| | cardiac surgery patients | physical therapy | causes |
| | Remote ischaemic preconditioning for | RIPC versus no | All-cause |
| | coronary artery bypass grafting (with or | RIPC (sham | mortality at 30 |
| | without valve surgery) | interventino) in | days |

| | | - |
|---|--------------------|----------------|
| | people | |
| | undergoing | |
| | CABG (with or | |
| | without valve | |
| | surgery) | |
| Prophylactic corticosteroids for | Corticosteroids vs | |
| cardiopulmonary bypass in adults | control | Mortality |
| Epidural analgesia for adults undergoing | Epidural analgesia | |
| cardiac surgery with or without | vs systemic | 30 day |
| cardiopulmonary bypass | analgesia | mortality |
| | Low-dose opioids | |
| | vs high-dose | |
| | opioids in opioid | Death at any |
| Fast-track cardiac care for adult cardiac | based cardiac | time after |
| surgical patients | anesthesia | surgery |
| | Early extubation | Death at any |
| Fast-track cardiac care for adult cardiac | after surgery vs | time after |
| surgical patients | usual care | surgery |
| | Statin vs | |
| HMG CoA reductase inhibitors (statins) | placebo/no | |
| for preventing acute kidney injury after | treatment after | |
| surgical procedures requiring cardiac | cardiac bypass | |
| bypass | procedures | Mortality |
| Transcatheter aortic valve implantation | Transcatheter | Short-term all |

| versus surgical aortic valve replacement for | aortic valve | cause |
|--|--------------------|---------------|
| severe aortic stenosis in people with low | implantation | mortality |
| surgical risk | versus surgical | |
| | aortic valve | |
| | replacement for | |
| | severe aortic | |
| | stenosis in people | |
| | with low surgical | |
| | risk | |
| | Transcatheter | |
| | aortic valve | |
| | implantation | |
| | versus surgical | |
| | aortic valve | |
| | replacement for | |
| Transcatheter aortic valve implantation | severe aortic | |
| versus surgical aortic valve replacement for | stenosis in people | Long-term all |
| severe aortic stenosis in people with low | with low surgical | cause |
| surgical risk | risk | mortality |
| Coronary Revascularization for Patients | | |
| with Diabetes Mellitus: A Contemporary | | 30 day |
| Systematic Review and Meta-Analysis | PCI vs CABG | mortality |
| Coronary Revascularization for Patients | | 1 year |
| with Diabetes Mellitus: A Contemporary | PCI vs CABG | mortality |

| Systematic Review and Meta-Analysis | | |
|---|-------------------|-----------------|
| Coronary Revascularization for Patients | | |
| with Diabetes Mellitus: A Contemporary | | 5 year |
| Systematic Review and Meta-Analysis | PCI vs CABG | mortality |
| | Off-pump CABG | All cause |
| Off-pump versus on-pump coronary artery | vs on-pump | mortality, any |
| bypass grafting for ischaemic heart disease | CABG | follow up |
| | Transmyocardial | |
| | laser | |
| | revascularization | |
| Transmyocardial laser revascularization | versus medical | |
| versus medical therapy for refractory | treatment for | Overall |
| angina | refractory angina | mortality |
| | Psychological | |
| Psychological interventions for coronary | intervention vs | |
| heart disease | usual care | Total mortality |
| | Fresh frozen | Short term |
| Fresh frozen plasma for cardiovascular | plasma vs no | mortality (30 |
| surgery | plasma | days) |
| Long-term and Temporal Outcomes of | | |
| Transcatheter Versus Surgical Aortic-valve | | 5 year all |
| Replacement in Severe Aortic Stenosis: A | | cause |
| Meta-analysis | TAVR vs SAVR | mortality |
| Perioperative beta-blockers for preventing | Perioperative | Early all-cause |

| surgery-related mortality and morbidity in | beta-blockers vs | mortality |
|--|------------------|----------------|
| adults undergoing cardiac surgery | control | |
| Perioperative beta-blockers for preventing | Perioperative | Long term all- |
| surgery-related mortality and morbidity in | beta-blockers vs | cause |
| adults undergoing cardiac surgery | control | mortality |
| | | |

504 Supplementary Results: Sensitivity analyses

In the 34 meta-analyses containing both RCTs and observational studies, the earliest 505 published study was an RCT in 8 (24%). In the 26 meta-analyses where observational studies were 506 published first, the median years until an RCT was published was 3 (IQR 1 to 6). Across these meta-507 analyses, comparing only the observational studies published before the first RCT appeared, the 508 summary of the relative summary effects was 0.93 (95% CI, 0.67-1.28), p=0.64, $I^2=4\%$ (0 to 34%). 509 Of 6 meta-analyses where the observational effect was statistically significant (p<0.005), only 510 511 1 also showed the RCT effect to be statistically significant. Of 2 meta-analyses where the RCT effect was statistically significant (p < 0.005), 1 also showed a significant observational effect. 512 Of the 824 studies, 416 (50%) were type A comparisons (comparing a newer less invasive 513 514 method versus an older more invasive method looking at non-inferiority). In sensitivity analysis flipping the coining of type A comparisons, the median observational summary effect across the 34 515

516 comparisons with both RCTs and observational studies was 0.89 (IQR, 0.1 to 1.16) versus an RCT

effect of 0.86 (IQR, 0.59 to 1.03) (p=0.47). The median relative summary effect was 1.16 (IQR, 0.80

to 1.63) and the summary of the relative summary effects 1.03 (0.82 to 1.31, p=0.79).